Alerta

PEPTIDE WITH NEUTRALIZING ACTIVITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2

Resumen de: US20260159544A1

The present invention relates to a peptide that specifically recognizes a protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or a portion thereof, a composition for preventing or treating SARS-CoV-2 infection, comprising the peptide; and a composition for detecting SARS-CoV-2, comprising the peptide.

METHOD FOR TREATMENT OF CORONAVIRUS INFECTION

Resumen de: US20260158055A1

The present invention involves a novel method for treatment of coronavirus infection, including SARS-COV-2. The method comprises administering stannous protoporphyrin and/or cyanocobalamin to a human patient at risk for developing complications from coronavirus infection. The method is particularly useful where a patient has been diagnosed with coronavirus infection or has been exposed to coronavirus but has not developed symptoms of coronavirus infection.

SYNTHESIS OF (1R,2S,5S)-N-(1S)-1-CYANO-2-(2-OXOINDOLIN-3-YL)ETHYL-3-(2S)-3,3-DIMETHYL-2-(2,2,2-TRIFLUOROACETYL)AMINOBUTANOYL-6,6-DIMETHYL-3-AZABICYCLO3.1.0HEXANE-2-CARBOXAMIDE

Resumen de: WO2026122604A1

The present invention is directed to method of synthesis of (1R,2S,5S)-N-(1S)-1-cyano-2- (2-oxoindolin-3-yl)ethyl-3-(2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetyl)aminobutanoyl-6,6- dimethyl-3-azabicyclo3.1.0hexane-2-carboxamide, which are useful in the treatment of coronavirus infection including COVID-19 resulting from SARS-CoV-2 infection.

COMPOSITION FOR THE TREATMENT OF COVID-19

Resumen de: US20260158044A1

0000 A composition for the treatment of COVID-19 is disclosed, including a first composition including approximately 10 mg of dexamethasone. The first composition is combined with a second composition including between approximately 48 mg to approximately 80 mg of triamcinolone acetonide, sodium chloride, benzyl alcohol, carboxymethylcellulose sodium, and polysorbate 80.

At-Home Covid Nucleic Acid Detection Kit For Rapid Molecular Diagnostics

Resumen de: US20260158492A1

The present invention describes kits and methods for rapid detection of nucleic acid sequences in real-time and in any setting. Unique features of this kit include isothermal nucleic acid extraction in Unit 1, and amplification, labeling, and signal detection in Unit 2 (FIG. 1). These units can be operated separately with manual transfer of product from one to the other or can be put together in a fashion where user places sample into inlet of Unit 1 and observes results in detection chamber of Unit 2. Several versions of this kit can be developed using different sequence-specific primers and probes to detect any nucleic acid sequence (DNA or RNA) in a multiplex fashion. In a preferred embodiment, visual detection of amplified signal is done using Lateral Flow Strips, eliminating the need for any additional complex equipment. Such a kit can be easily developed and manufactured to assist in the mitigation response to any pandemic, especially for COVID-19. The COVID-19 kit is called an At-Home COVID test (AH-COV).

METHODS OF ASSIGNING A COVID PATHOLOGICAL TYPE AND COMPOSITIONS FOR PRACTICING THE SAME, AND METHODS OF TREATING A SUBJECT FOR CHRONIC COVID-19

Resumen de: WO2025029797A1

Methods of assigning a COVID pathological type for a subject suffering from COVID-19 are provided. Aspects of the methods include assigning a COVID pathological type for the subject based on a determined quantitative, multiplex cytokine/chemokine panel in a test sample from the subject. Also provided are methods of treating a subject (e.g., a long hauler subject) for chronic COVID-19. Aspects of such methods include administering to the long hauler subject a CCR5/CCL5 interaction inhibitor to treat the long hauler subject. Also provided are compositions for use in practicing the methods. The methods and compositions find use in a variety of applications, including patient stratification, treatment and therapy determination and therapy response assessment.

A SARS-COV-2 NUCLEOCAPSID PROTEIN-SPECIFIC VNAR ISOLATED FROM A NAÏVE PHAGE LIBRARY

Resumen de: WO2026112937A1

Relate to an isolated vNAR single domain antibody that specifically binds to SARS-CoV-2 nucleocapsid protein, and a process for preparing the same.This isolated vNAR single domain antibody are also included.

COMPOSITIONS AND THERAPEUTIC METHODS FOR TREATING CHRONIC SEQUALAE FOLLOWING VIRAL INFECTIONS

Resumen de: US20260151414A1

0000 Embodiments of therapeutic protocols to treat Post-Acute Sequelae SARS-COV-2 infection (“PASC”), a.k.a. “long Covid,” are described. The PASC treatment protocols focus on a moderating a hyperimmune response; destroying and removing the SARS COV-2 spike protein from the gut and body, detoxifying the body and the brain; replenishing key nutrients; mitigating depression and anxiety; and a regimen of physical and mental exercises. A standard six-week protocol and a shorter, three-week protocol are disclosed for those with a milder form of PASC are disclosed.

ANTIVIRAL PRODRUGS, INTERMEDIATE-AND LONG-ACTING FORMULATIONS AND METHODS

Resumen de: US20260151415A1

0000 Compounds and pharmaceutical formulations including a compound and an oil, which may be formulated for intermediate- or long-acting intramuscular injection. Methods for treating respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), coronavirus, SARS CoV-2, and other RNA virus infections in mammals.

BROAD-SPECTRUM MULTI-ANTIGEN PAN-CORONAVIRUS VACCINE

Resumen de: US20260151476A1

0000 Waning immunity induced by first-generation Spike-alone-based COVID-19 has failed to prevent immune escape by many variants of concern (VOCs) that emerged from 2020 to 2024, resulting in a prolonged COVID-19 pandemic. Thus, a next-generation Coronavirus (CoV) vaccine incorporating highly conserved non-Spike SARS-COV-2 antigens is described herein. Conserved non-Spike T cell antigens in combination with a Spike antigen encapsulated in lipid nanoparticles: (i) Induced high frequencies of lung-resident antigen-specific CXCR5+CD4+ T follicular helper cells, GzmB+CD4+ and GzmB+CD8+ cytotoxic T cells, and CD69+IFN-γ+TNFα+CD4+ and CD69+IFN-γ+TNFα+CD8+ effector T cells; and (ii) Reduced viral load and COVID-19-like symptoms caused by various VOCs. The combined antigen/LNP-based pan-CoV vaccine could be rapidly adapted for clinical use to confer broader cross-protective immunity against emerging highly mutated and pathogenic VOCs.

COMPOSITIONS AND METHODS FOR TREATING BIOFILMS AND NEUTROPHIL EXTRACELLULAR TRAP FORMATION

Resumen de: US20260152531A1

0000 Provided herein is a synthetic polypeptide derived from High Mobility Group Box 1 (HMGB 1) host protein that can both disrupt bacterial biofilms and prevent Neutrophil Extracellular Trap (NET) formation. Also provided herein are methods to disrupt aberrant or excessive NET formation that are particularly well-suited to treat high-risk populations such as those infected with SARS CoV-2, sepsis, autoimmune diseases e.g., systemic lupus erythematosus, rheumatoid arthritis, Type I diabetes mellitus, small vessel vasculitis, autoinflammatory diseases e.g., gout, inflammatory bowel disease, and metabolic diseases e.g., Type 2 diabetes and obesity.

COVID-19 Treatment of COVID-19 and Methods Therefor

Resumen de: JP2025032179A

To provide a vaccine composition to induce immunity against a coronavirus in a subject.SOLUTION: A vaccine composition comprises a recombinant nucleic acid that encodes N-ETSD, a modified nucleocapsid protein that includes an endosomal targeting sequence, and/or that encodes S-Fusion, a modified spike protein that has improved surface expression. The vaccine may be formulated as a recombinant nucleic acid, recombinant yeast, and/or recombinant virus such as an adenovirus and can be administered via injection and/or mucosal delivery.SELECTED DRAWING: Figure 25

SYSTEM FOR DIAGNOSIS OF RESPIRATORY DISEASES USING ANALYSIS OF EXHALED BREATH AND AEROSOLS

Resumen de: EP4751641A2

Disclosed are methods and devices for analyzing non-volatile organics in exhaled breath and other aerosols using various diagnostic tools that enable rapid, low cost point of care assays for several diseases including respiratory tract diseases such as COVID-19. The disclosed methods and systems selectively capture non-volatile organics in exhaled breath and other aerosols in a packed bed column. The non-volatile organics are eluted and samples are analysis using diagnostic devices including MALDI-TOFMS. The disclosed systems and methods provide for a diagnostic test result in less than about 20 minutes and provides for autonomous operation with minimal human intervention.

ANTIBODIES AGAINST COVID-19 AND OTHER HUMAN CORONAVIRUSES

Resumen de: WO2025022303A1

The present invention relates to monoclonal antibodies or antigen-binding portion thereof that have a potent neutralizing activity against Coronavirus, in particular against at least one virus selected from SARS-CoV-2, SARS-CoV-1 and variants thereof. The invention relates also to the use of such monoclonal antibodies or antigen-binding portion thereof in therapy, prophylaxis, and diagnosis of Coronavirus, in particular SARS-CoV-2 and/or SARS-CoV-1 dependent diseases.

IMPROVED METHODS OF PRODUCING A LIPIDATED PROTEIN

Nº publicación: EP4751733A2 03/06/2026

Solicitante:

VALNEVA AUSTRIA GMBH [AT]
Valneva Austria GmbH

Resumen de: EP4751733A2

The present invention relates to method of producing a lipidated protein, a pharmaceutical composition comprising the protein of any of SEQ ID NOs: 1, 2, and/or 3 and/or the lipidated form of a protein comprising the protein of SEQ ID NO: 7 (C-TAB.GS) and/or SEQ ID NO: 8 (C-TAB.G5.1), especially the protein of SEQ ID NO: 12 (Lip-C-TAB.G5.1), and/or a lipidated form of a protein comprising the protein of SEQ ID NO: 15 (Spike protein of SARS-CoV-2) and/or a lipidated form of a protein comprising the any of the proteins of SEQ ID NOs: 16-22 (hMPV F protein), and the pharmaceutical composition for use as a medicament, particularly a vaccine and/or for use in a method for eliciting an immune response in a human against Lyme disease, a disease caused by Clostridium difficile or hMPV and/or of SARS-CoV-2 (COVID-19).